Marksans Pharma has announced a positive update regarding its US operations. The company shared that its wholly owned subsidiary, Time-Cap Laboratories Inc., based in Farmingdale, New York, has successfully received the Establishment Inspection Report (EIR) from the USFDA.
This follows a routine cGMP (current Good Manufacturing Practices) inspection that took place from April 16 to April 24, 2025. The inspection covered the site’s compliance with quality standards, and the EIR indicates a satisfactory outcome.
For those unfamiliar, Marksans Pharma is a Mumbai-headquartered pharmaceutical company that specializes in research, manufacturing, and global marketing of generic medicines. Its facilities are approved by top global regulators like the USFDA, UKMHRA, and Australia’s TGA.
The company’s product lineup spans key therapeutic areas, including cardiovascular, central nervous system, diabetes care, pain relief, gastrointestinal health, and allergy treatment—and it’s actively selling these in markets around the world.
This USFDA approval reinforces Marksans Pharma’s commitment to maintaining high-quality standards and its steady expansion in regulated markets.
